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Abstract
Introduction Approximately one-third of patients with
type 2 diabetes mellitus (T2DM) have concurrent renal
impairment. There are limited therapeutic options for these
patients. Fasiglifam is a G protein-coupled receptor 40
agonist that was under investigation for the treatment of
T2DM. The objective of this study was to evaluate the
potential effect of renal impairment on the pharmacoki-
netics and safety of a single dose of fasiglifam and its
metabolite M-1.
Methods This was a phase I, open-label, parallel-group
study. Subjects with varying degrees of renal function
received a single oral dose of fasiglifam 50 mg. Blood and
urine samples were collected through 168 h postdose.
Study endpoints were pharmacokinetic and safety
variables.
Results Fifty-three subjects were enrolled. Mean fasigli-
fam plasma concentrations were higher in subjects with
mild renal impairment compared with other groups, but
within each renal function cohort, plasma concentrations
tended to decrease with decreasing renal function.
Regression analyses indicated that fasiglifam exposure
decreased and M-1 exposure increased with decreasing
renal function. Predicted exposure values at about the
midpoint of creatinine clearance for each renal impairment
group differed by up to 21 % (fasiglifam) and 87 % (M-1)
from that of the normal renal function group. Hemodialysis
had no effect on fasiglifam or M-1 exposure. Fasiglifam
renal clearance (CLR) was not affected, but M-1 CLR
decreased with increasing impairment. No incidences of
hypoglycemia were reported during the study.
Conclusion Varying renal function status did not have a
significant impact on the clearance of fasiglifam in this
study.
Key Points
Fasiglifam is a potent and highly selective agonist of
the G protein-coupled receptor 40
Varying degrees of renal function in subjects with
type 2 diabetes mellitus did not have a significant
impact on fasiglifam exposure
1 Introduction
Diabetes mellitus is a global health concern, with a pre-
dicted prevalence rate of 552 million by the year 2030 [1].
Approximately 90 % of patients with diabetes have type 2
diabetes mellitus (T2DM) [2]. Up to 35 % of patients with
T2DM have some form of renal impairment [3–5]. This
prevalence may be even higher, as many patients have
undiagnosed renal impairment [3, 4].
Renal impairment is a common occurrence among
patients with T2DM [3] and may often impede and com-
plicate adequate glycemic control by pharmacotherapy [6].
Insulin secretagogues such as sulfonylureas and glinides
are known to cause hyperinsulinemia and are associated
with the risk of hypoglycemia [7]. Dose adjustments are
often recommended when these secretagogues are used to
treat T2DM patients with renal impairment [6]. Other
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antidiabetic medications such as metformin or some
dipeptidyl peptidase 4 inhibitors may be contraindicated or
need a dose adjustment in T2DM patients with renal
impairment because they are mainly eliminated by the
kidneys [8, 9]. Thus, there remains an unmet medical need
for effective and safe antidiabetic medications in T2DM
patients with renal impairment, as many currently available
drugs are contraindicated, not suitable for use in such a
population, or have to be dose adjusted [10]. There is a
need for an agent that can stimulate insulin secretion and
can be used in patients with various levels of renal
impairment without the concern of dose adjustment or the
risk of hypoglycemia.
Fasiglifam (TAK-875), a potent and highly selective
agonist of the G protein-coupled receptor 40 (GPR40), was
under investigation as an adjunct to diet and exercise to
improve glycemic control in patients with T2DM [11, 12].
GPR40 is highly expressed in pancreatic b cells and is
activated by the binding of medium- or long-chain free
fatty acids, which augments glucose-stimulated insulin
secretion [13]. The novel mechanism of action of fasigli-
fam potentiates the activity of GPR40, thus stimulating
insulin secretion only at elevated blood glucose concen-
trations [12, 14]. In contrast, insulin secretagogues, such as
glinides and sulfonylureas, stimulate insulin secretion even
at low blood glucose concentrations [7], which can lead to
hypoglycemia. In phase II clinical trials, fasiglifam dem-
onstrated clinically and statistically significant improve-
ments in glycemic control in T2DM patients with
inadequate control through diet and exercise with or
without metformin [15–17]. Fasiglifam was well tolerated
in healthy volunteers and subjects with T2DM, and the
incidence of hypoglycemia was low and not different from
placebo [15–19]. However, because of liver safety con-
cerns, the clinical development of fasiglifam was termi-
nated in December 2013. This decision was a result of liver
test data in subjects indicating drug-induced liver injury.
In healthy volunteers, single doses of fasiglifam
(25–800 mg) were rapidly absorbed, reaching peak plasma
concentrations in 3–4 h, with a terminal elimination half-
life (t1/2) of 28–30 h [19]. Increases in exposure were
approximately dose dependent. Fasiglifam is metabolized
to a minor inactive metabolite, fasiglifam M-1 [19]. Renal
clearance (CLR) plays a minimal role in total fasiglifam
clearance. Multiple dosing of fasiglifam (25–400 mg) in
subjects with T2DM led to increased exposure at day 14
that was roughly three times that of the corresponding
single dose, primarily because of lower clearance rates
[17]. Although CLR of fasiglifam was found to be minimal
in healthy volunteers, [19] renal impairment can inhibit
some pathways of hepatic and intestinal metabolism [20].
The primary objective of this study was to evaluate the
effect of renal impairment on the pharmacokinetics (PK) of
a single oral 50-mg dose of fasiglifam and its metabolite
M-1 in subjects with varying degrees of renal function.
2 Materials and Methods
2.1 Subjects
Male or female volunteers 18–80 years of age who were
considered by the investigator to be healthy except for
controlled hypertension or diabetes and problems associ-
ated with the primary diagnosis of renal impairment, with a
body weight of C50 kg and a body mass index between
19.0 and 36.0 kg/m2 were eligible to enroll. Additional
inclusion criteria included a creatinine clearance (CLCR)
C90 mL/min for subjects with normal renal function, C60
to \90 mL/min for subjects with mild renal impairment,
C30 to \60 mL/min for subjects with moderate renal
impairment, and \30 mL/min for subjects with severe
renal impairment [21]. Subjects with end-stage renal dis-
ease (ESRD) were on intermittent hemodialysis.
Exclusion criteria included, but were not limited to, a
predisposition to easy bruising or bleeding disorders; a
medical history of gastric or duodenal ulceration; any
trauma within 1 week of screening; extensive ecchymosis;
hemoptysis; gingival bleeding; hematemesis; repeated or
significant nose bleeds; peri-orbital hematoma; retinal
detachment; menorrhagia; hematuria; melanoma; an acute
clinically significant illness within 30 days prior to day -1;
a history of abdominal, thoracic, or nonperipheral vascular
surgery within 6 months prior to day -1; a history of
cancer other than basal cell or stage 1 squamous cell car-
cinoma of the skin that had not been in remission for
C5 years prior to day -1; any protocol-specified prohib-
ited medications or supplements; a serum creatinine kinase
level[3 times the upper limit of normal; sustained systolic
blood pressure C155 mmHg or B90 mmHg or a diastolic
blood pressure C95 mmHg or B50 mmHg; resting pulse
rate of \51 or [100 beats per minute; abnormal electro-
cardiogram (ECG) at screening or check-in day; alanine
aminotransferase or aspartate aminotransferase level [1.5
times the upper limit of normal; active liver or gall bladder
disease; or a history of drug/alcohol abuse.
2.2 Study Design
The study was conducted in compliance with the institu-
tional review board regulations, Good Clinical Practice
regulations and guidelines, and all applicable local regu-
lations. This was a phase I, open-label, parallel-group
study. The use of a single dose of fasiglifam in this study
was chosen because the multiple-dose PK parameters of
fasiglifam and M-1 are linear and time independent [17]
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and, therefore, can be extrapolated from single-dose PK
studies. All subjects received a single oral dose of fasi-
glifam 50 mg (Takeda Pharmaceutical Co. Ltd, Osaka,
Japan) in the morning after an overnight fast of C10 h;
subjects with ESRD requiring dialysis fasted for C2 h.
Subjects were admitted to the clinic on day -1 and were
confined to the clinic until the collection of the 168-h
postdose PK samples on day 8 and the completion of all
scheduled procedures. Standardized meals containing 30 %
fat were provided to all subjects during the confinement
period.
Up to 64 subjects were planned for enrollment in the
study: up to 32 subjects with normal renal function and
eight within each category of renal impairment. Subjects
with normal renal function were matched by sex, weight,
age, and smoking status. Subjects with normal renal
function could be matched to more than one subject with
renal impairment, but to no more than one subject within
each impairment group.
2.3 Sample Collection
For the determination of plasma concentrations of fasigli-
fam and its metabolite M-1, blood samples (4 mL) were
collected from all subjects at 15 min predose and at 0.5, 1,
1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and
168 h postdose. For subjects with ESRD, additional 4-mL
arterial samples were collected at 1, 2, 3, and 4 h postdose
(if subjects were still on dialysis). Three (10 mL) blood
samples were collected 15 min predose from all subjects
for protein-binding assessments. All voided urine was
collected from subjects with normal renal function, and
mild, moderate, and severe renal impairment at -12 to 0 h
predose, and then at 24-h intervals up to 7 days postdose.
2.4 Plasma Protein Binding
The in vitro protein binding of fasiglifam was determined
ex vivo using ultracentrifugation of predose plasma sam-
ples from the study subjects spiked with [14C] fasiglifam at
a nominal concentration of 1 lg/mL.
2.5 Analytical Methods
Plasma and urine concentrations of fasiglifam and fasigli-
fam M-1 were measured using validated liquid chroma-
tography with tandem mass spectrometry with a range of
5.00–10,000 ng/mL.
2.6 Pharmacokinetic Assessments
The PK parameters of fasiglifam and fasiglifam M-1 were
derived using non-compartmental analysis methods with
Phoenix WinNonlin Version 6.3 (Pharsight Corp, Cary,
NC, USA). Measurements below the limit of quantification
of 5.00 ng/mL were treated as 0 when deriving PK
parameters. The PK parameters assessed for fasiglifam and
fasiglifam M-1 (unless otherwise specified) included
maximum observed plasma concentration (Cmax); time to
Cmax (Tmax); area under the plasma concentration-time
curve (AUC) from time 0 to the time of last quantifiable
concentration (t), calculated using the linear trapezoidal
rule (AUCt); area under the plasma concentration-time
curve from 0 to infinity calculated from AUCt ? lqc/kz,
where lqc is the last quantifiable concentration and kz is the
terminal elimination rate constant, calculated as the nega-
tive of the slope of the log-linear regression of the natural
logarithm concentration-time curve during the terminal
phase (AUC?); t1/2 calculated as ln (2)/kz; apparent
clearance after extravascular administration, calculated as
dose/AUC? after a single dose (CL/F; calculated for
fasiglifam only); apparent volume of distribution during
the terminal phase after extravascular administration, cal-
culated as (CL/F)/kz (Vz/F; for fasiglifam only); area under
the unbound plasma concentration-time curve from time 0
to infinity, calculated as AUC? percent unbound
(AUC?,u; calculated for fasiglifam only); maximum
observed unbound plasma concentration (Cmax,u; calculated
for fasiglifam only); oral clearance of unbound fasiglifam,
calculated as CL/F percent unbound (CLu/F; calculated for
fasiglifam only).
The urinary parameters included total amount of drug
excreted in urine from time 0 to time t (Aet); fraction of
drug excreted in urine, calculated as (Aet/dose) 9 100 (fR;
calculated for fasiglifam only); and CLR calculated as Aet/
AUCt.
2.7 Safety Assessments
Physical examinations and 12-lead ECGs were performed
on day -1, predose, and at study exit or early termination
(ET). Vital signs were examined on day -1, predose on day
1, and 1, 2, 4, 8, 12, 24, and 48 h postdose, and at study exit
or ET. Clinical laboratory evaluations comprising routine
hematology, serum chemistry, and urinalysis were included
in the safety assessments. Participants were also monitored
for adverse events (AEs) and the incidence of hypoglycemia.
Blood glucose was measured by fingerstick prior to break-
fast (predose on day 1); at lunch and dinner during con-
finement, which lasted from day -1 to study exit on day 8; or
if signs or symptoms of hypoglycemia occurred.
2.8 Statistical Analyses
The safety analysis set, which included all subjects who
were enrolled in the study and received the study drug,
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was used for demographics and safety summaries. The PK
set included all subjects with one or more measurable
concentration(s) of fasiglifam. Descriptive statistics [N,
mean, standard deviation (SD), percent coefficient of
variation (%CV), median, minimum, and maximum] were
used to summarize plasma concentrations of fasiglifam
and fasiglifam M-1 by renal function group and collection
time point. Similar descriptive statistics were used to
summarize the plasma and urine PK parameters of fasi-
glifam and fasiglifam M-1, and the percent of unbound
fasiglifam in plasma by renal function group. In addition,
geometric means were calculated for Cmax and AUC. The
relationship between renal function and fasiglifam Tmax,
Cmax,u, AUC?,u, kz, and CLu/F were evaluated with
regression analyses. CLCR was a continuous variable in
the regression model. Based on the results from the
regression models for each PK parameter, individual
parameter predictions and the 95 % prediction intervals
were calculated for a hypothetical subject with CLCR at
about the midpoint of each renal function category. Sub-
jects with ESRD were not included in the regression
analyses because CLCR was not determined in these
subjects. Instead, an analysis of covariance with renal
function as the factor and baseline weight as the covariate
was used to compare the PK of ESRD subjects with that
of normal subjects.
3 Results
3.1 Subject Disposition and Baseline Characteristics
Of 168 subjects initially screened, 53 were enrolled and
completed the study (Fig. 1). Subjects had a mean age of
57 years and the majority were white (66.0 %). Subject
demographics and baseline characteristics were compara-
ble among the various groups (Table 1). Of the 32 subjects
with renal impairment, 14 (43.8 %) had concurrent T2DM
(Table 1).
3.2 Pharmacokinetic Analyses
Following oral administration of a single 50-mg dose of
fasiglifam, mean plasma concentrations tended to be higher
in subjects with mild renal impairment compared with
subjects in other groups. Within the treatment groups with
varying degrees of renal impairment, plasma concentra-
tions tended to be lower with decreasing renal function
throughout the time course (Fig. 2a). There was no con-
sistent trend of increasing mean plasma concentrations of
the inactive metabolite fasiglifam M-1 with increasing
severity of renal impairment, although concentrations were
generally higher in subjects with renal impairment com-
pared with those with impaired renal function (Fig. 2b).
Fig. 1 Disposition of subjects. CLCR creatinine clearance, ESRD end-
stage renal disease. Normal renal function, CLCR C90 mL/min; mild
renal impairment, CLCR = 60 to \90 mL/min; moderate renal
impairment, CLCR = 30 to \60 mL/min; severe renal impairment,
CLCR \30 mL/min. Note: Subjects with normal renal function could
be matched to more than one subject with renal impairment, but to no
more than one subject within each impairment group
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The mean percent unbound fasiglifam values in plasma
were slightly higher in subjects with normal renal function
(0.17 % unbound) than in subjects with mild, moderate, or
severe renal impairment and subjects with ESRD requiring
dialysis (0.11–0.15 % unbound).
Descriptive statistics for the noncompartmental PK
parameter estimates (in plasma and urine) of fasiglifam and
fasiglifam M-1 following the administration of a single
50-mg dose of fasiglifam to subjects with normal renal
function, renal impairment, or with ESRD requiring dial-
ysis are summarized in Tables 2 and 3, respectively.
Fasiglifam plasma PK parameters were comparable
between subjects with normal renal function and those with
mild, moderate, or severe renal impairment. Among the
urinary PK estimates of fasiglifam, the fR was estimated to
be B0.35 % and CLR varied from 0.0015 to 0.0025 L/h
across all subject groups. Mean plasma concentrations of
fasiglifam M-1 were lower than those of the parent drug,
with metabolite-to-parent AUC ratios from 0.11 to 0.55
(Table 3). Mean arterial and venous plasma concentrations
of fasiglifam or fasiglifam M-1 were similar to each other
during dialysis, but concentrations of fasiglifam M-1 were
lower than those of the parent drug (Fig. 3).
Regression analyses were performed on the fasiglifam
PK parameters Tmax, Cmax,u, AUC?,u, CLu/F, and kz vs
CLCR for subjects with normal renal function and with
mild, moderate, or severe renal impairment (Table 4).The
median times to reach Cmax were similar across subjects
with normal renal function and mild, moderate, or severe
renal impairment. Regression analyses showed a nonsta-
tistically significant linear relationship between Tmax and
CLCR. Regression analyses showed a nonstatistically sig-
nificant trend between Cmax,u, AUC?,u, or CLu/F, and
CLCR. A 19 % decrease in the predicted Cmax,u values was
Table 1 Subject demographics and baseline characteristics
Characteristic Renal impairment status
Normal (n = 21) Mild (n = 8) Moderate (n = 8) Severe (n = 8) ESRDa (n = 8)
Age (years)
Mean (SD) 52.5 (11.25) 61.8 (9.13) 65.1 (10.06) 60.0 (11.01) 51.5 (10.76)
Range 29–71 47–74 49–76 41–72 39–66
Sex
Male 11 (52.4) 6 (75.0) 3 (37.5) 3 (37.5) 5 (62.5)
Race
Asian 1 (4.8) 2 (25.0) 1 (12.5) 0 (0.0) 0 (0.0)
Black or African American 0 (0.0) 2 (25.0) 1 (12.5) 5 (62.5) 6 (75.0)
White or Caucasian 20 (95.2) 4 (50.0) 6 (75.0) 3 (37.5) 2 (25.0)
Height (cm)
Mean (SD) 166.6 (7.79) 165.4 (7.78) 162.8 (13.38) 166.5 (6.00) 171.1 (10.89)
Range 153–178 158–179 145–184 158–177 160–190
Weight (kg)
Mean (SD) 80.1 (10.04) 74.2 (8.90) 77.8 (25.08) 75.9 (15.13) 83.1 (22.49)
Range 64–98 65–87 51–120 51–100 52–116
BMI (kg/m2)
Mean (SD) 28.8 (2.69) 27.2 (3.04) 28.8 (5.31) 27.2 (4.41) 28.2 (6.69)
Range 24–34 25–33 21–35 20–36 17–40
CrCl (mL/min)
Mean (SD) 121.0 (25.19) 71.0 (9.52) 46.3 (9.32) 21.3 (4.76) NC
Range 91–170 61–86 31–60 13–29 NC
eGFR (mL/min)
Mean (SD) 104.2 (24.10) 72.8 (15.77) 43.7 (14.98) 18.1 (3.75) 8.2 (2.64)
Range 66–148 54–103 18–59 11–21 6–13
Diabetes mellitus 0 2 (25) 4 (50) 5 (62.5) 3 (37.5)
Data are presented as n (%), unless otherwise stated
a ESRD requiring dialysis
Normal renal function, CrCl C90 mL/min; mild renal impairment, CrCl = 60 to \90 mL/min; moderate renal impairment, CrCl = 30 to
\60 mL/min; severe renal impairment, CrCl \30 mL/min, ESRD end-stage renal disease, SD standard deviation, BMI body mass index, CrCl
creatinine clearance, eGFR estimated glomerular filtration rate, NC not calculated
Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam 277
estimated with a decline in renal function from normal to
severe (p = 0.111). This was accompanied by a 21 %
decrease in predicted AUC?,u values (p = 0.114) and a
40 % increase in the predicted CLu/F values (p = 0.063)
with declining renal function.
Linear regression analyses of fasiglifam M-1 Cmax,
AUC?, and kz vs CLCR showed statistically significant
linear trends. The predicted Cmax of fasiglifam M-1 pro-
gressively increased from 75.2 to 110.1 ng/mL, as the renal
function decreased from normal to severe, representing an
approximate 47 % increase from the mean Cmax of the
subjects with normal renal function. For fasiglifam M-1 kz,
the predicted decrease with decreasing renal function was
estimated to be approximately 27 % when compared with
the normal renal function group. Linear regression analyses
of Tmax on CLCR did not show a statistically significant
linear relationship.
Scatter plots of fasiglifam Cmax,u and AUC?,u are
shown in Fig. 4a and 4b, respectively. The data are in
accordance with the regression analysis in showing that
Cmax,u and AUC?,u did not significantly differ between
subjects with normal renal function and those with mild,
moderate, or severe renal impairment.
The comparison of the results from the analysis of
covariance for the ESRD group with the normal group
(results not shown) is similar to the comparison of arith-
metic means provided in Table 2.
3.3 Safety Analyses
Thirteen of 53 subjects (24.5 %) had treatment-emergent
AEs (TEAEs): four (19.0 %) in the normal renal function
group, two (25.0 %), three (37.5 %), and three (37.5 %) in
the mild, moderate, and severe impairment groups,
Fig. 2 Mean concentration-
time profile of a fasiglifam and
b fasiglifam M-1 in a log-linear
scale following administration
of a single 50-mg dose of
fasiglifam in subjects with




renal disease. Normal renal
function, CLCR C90 mL/min;
mild renal impairment,
CLCR = 60 to \90 mL/min;
moderate renal impairment,
CLCR = 30 to \60 mL/min;
severe renal impairment, CLCR
\30 mL/min
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Table 2 Summary of fasiglifam plasma and urine pharmacokinetic parameter estimates following the administration of a single 50-mg dose of
fasiglifam to subjects with varying degrees of renal function
Renal function status
Normal (n = 21) Mild (n = 8) Moderate (n = 8) Severe (n = 8) ESRD a (n = 8)
Plasma pharmacokinetics
Tmax (h) 3.5 (2–8) 3.1 (2–6) 3.3 (2–4) 2.8 (2–6) 2.9 (1–6)
Cmax, u (ng/mL) 3.8 (1.60) 2.7 (0.72) 2.7 (1.33) 2.9 (1.35) 2.7 (1.78)
Cmax (ng/mL) 2306.2 (410.27) 2510.0 (811.79) 2352.9 (999.45) 2115.0 (941.50) 1920.0 (754.89)
AUC?, u (ngh/mL) 93.8 (39.46) 84.4 (41.75) 75.6 (37.11) 57.8 (42.49)b 56.2 (37.96)
AUCt (ngh/mL) 56922.4 (23597.59) 74298.1 (35300.40) 61238.9 (29707.92) 43533.1 (32163.52) 36302.2 (17109.84)
AUC? (ngh/mL) 61463.4 (28463.44) 77379.6 (37965.78) 66776.5 (34699.57) 47928.7 (41730.61)b 40030.5 (21278.40)
CLu/F (L/ h) 638.4 (317.30) 788.0 (5634.0) 938.5 (746.62) 1306.8 (856.98) 1392.3 (929.93)
CL/F (L/h) 1.0 (0.49) 0.9 (0.84) 1.2 (1.19) 1.7 (1.15)b 1.6 (0.88)
t1/2 (h) 48.6 (24.13) 34.5 (14.40) 51.0 (19.49) 38.8 (22.99)
b 53.9 (57.26)
Urine pharmacokinetics
Ae(0–168) (ng) 96476.6 (55826.49) 175079.3 (124841.58) 121740.4 (97466.30) 60965.1 (41220.11) NA
Fe (%) 0.2 (0.11) 0.4 (0.25) 0.2 (0.20) 0.1 (0.08) NA
CLr (L/h) 0.0 (0.00) 0.0 (0.00) 0.0 (0.00) 0.0 (0.00) NA
Tmax data presented as mean (range). All other data presented as mean (standard deviation)
a ESRD requiring dialysis
b n = 7
Ae(0–168) amount of drug excreted in urine from 0 to 168 hours, AUC? area under the plasma-concentration time curve from time zero to infinity,
AUC?, u area under the unbound plasma concentration time curve from time zero to infinity, AUCt AUC from time 0 to the time of last
quantifiable concentration (t), calculated using the linear trapezoidal rule, CL/F oral clearance of fasiglifam, CLu/F oral clearance of unbound
fasiglifam, CLr renal clearance, CrCl creatinine clearance, Cmax maximum plasma concentration, Cmax, u maximum observed unbound plasma
concentration, ESRD end-stage renal disease, Fe Fraction of drug excreted in urine, NA not available, Tmax time to maximum plasma
concentration, t1/2 elimination half-life
Normal renal function, CrCl C90 mL/min; mild renal impairment, CrCl = 60 to \90 mL/min; moderate renal impairment, CrCl = 30 to
\60 mL/min; severe renal impairment, CrCl\30 mL/min
Table 3 Summary of fasiglifam M-I plasma and urine pharmacokinetic parameter estimates following the administration of a single 50-mg dose
of fasiglifam to subjects with varying degrees of renal function
Renal impairment status
Normal (n = 21) Mild (n = 8) Moderate (n = 8) Severe (n = 8) ESRDa (n = 8)
Plasma pharmacokinetics
Cmax (ng/mL) 65.6 (37.93) 101.3 (50.13) 68.1 (25.31) 128.1 (96.79) 61.3 (47.02)
Tmax (h) 25.7 (8–96) 27.0 (12–48) 26.8 (10–48) 43.0 (10–120) 40.9 (10–72)
AUCt (ngh/mL) 5483.0 (3831.54) 8708.3 (4922.80) 6705.4 (2486.99) 14617.0 (11135.73) 7094.1 (6403.08)
AUC? (ngh/mL) 6693.4 (5380.13) 10541.9 (7232.45) 7185.5 (1322.72)b 21301.3 (20066.72)c 11273.3 (13504.13)b
t1/2 (h) 49.5 (24.36) 56.6 (22.62) 56.0 (23.55)
b 98.4 (53.35)c 88.5 (38.74)b
AUC ratio 0.11 (0.07) 0.18 (0.20) 0.19 (0.18)b 0.55 (0.32)c 0.27 (0.18)b
Urine pharmacokinetics
Ae(0–168) (ng) 161136.7 (187146.46) 215446.2 (178864.48) 58352.2 (81425.03) 27961.1 (50658.34) NA
CLr (L/h) 0.03 (0.018) 0.02 (0.011) 0.01 (0.011) 0.00 (0.004) NA
Tmax data presented as mean (range). All other data presented as mean (standard deviation)
a ESRD requiring dialysis; b n = 7; c n = 6
Normal renal function, CrCl C90 mL/min; mild renal impairment, CrCl = 60 to \90 mL/min; moderate renal impairment, CrCl = 30 to
\60 mL/min; severe renal impairment, CrCl\30 mL/min. Ae(0–168) amount of drug excreted inurine from 0 to 168 hours, AUCt AUC from time
0 to the time of last quantifiable concentration (t), AUC? area under the plasma-concentration time curve from time zero to infinity, CLr renal
clearance, Cmax maximum plasma concentration, CrCl creatinine clearance, ESRD end-stage renal disease, NA not available, Tmax time to
maximum plasma concentration, t1/2 elimination half-life
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respectively, and one (12.5 %) in the ESRD group. All
TEAEs were experienced by single subjects except head-
ache, nasopharyngitis, and nausea, which were experienced
by two subjects each. The majority of TEAEs were mild in
intensity. Two subjects had TEAEs that were considered
moderate in intensity: abdominal pain (one subject with
mild renal impairment) and increased blood pressure (one
subject with moderate renal impairment). One serious AE,
an acute myocardial infarction, occurred in a 74-year-old
male subject with T2DM, hyperlipidemia, and mild renal
impairment. This event occurred 18 days after adminis-
tration of a single dose of fasiglifam 50 mg and resolved
after 4 days, was not considered to be related to study drug,
and did not lead to study discontinuation. No TEAEs or
laboratory test results were reported in any subjects that led
to study discontinuation. None of the subjects developed
hypoglycemia in the study.
4 Discussion and Conclusion
In the present study, we evaluated the impact of varying
degrees of renal impairment on the PK of fasiglifam
regarding the use of this novel agent in patients with T2DM
and chronic kidney disease. No major differences in the
main PK parameters were found.
As the differences in protein binding between renal
function groups were small, major differences in systemic
clearance between healthy subjects and those with renal
impairment based on the protein binding of the parent drug
would not be expected. Generally, it would be expected
that, following the administration of a drug to a subject
with renal impairment, plasma exposure would be higher
compared with that in a subject with normal renal function
owing to the decrease in renal clearance of the drug.
However, in this study, the renal clearance of fasiglifam
Fig. 3 Mean fasiglifam and
fasiglifam M-1 arterial and
venous plasma concentration-
time curves in log-linear scale
following the administration of
a single 50-mg dose of
fasiglifam to subjects with
ESRD during dialysis. ESRD
end-stage renal disease
Table 4 Prediction and 95 % prediction intervals for various degrees of renal function (CrCl) based on regression models for the relationship
between renal function and fasiglifam pharmacokinetic parameters
Renal impairment status
Parameter Normal (CrCl = 100
mL/min)
Mild (CrCl = 65 mL/min) Moderate (CrCl = 40
mL/min)
Severe (CrCl = 20 mL/min)
Prediction 95 % PIa Prediction 95 % PIa Prediction 95 % PIa Prediction 95 % PIa
AUC?, u (ngh/mL) 86.99 73.89, 100.10 79.16 66.07, 92.26 73.57 56.58, 90.56 69.10 47.81, 90.38
Cmax, u (ng/mL) 3.40 2.94, 3.87 3.13 2.67, 3.58 2.93 2.35, 3.52 2.78 2.04, 3.51
Tmax (h) 3.31 2.84, 3.77 3.22 2.76, 3.67 3.15 2.57, 3.74 3.10 2.37, 3.83
kz (L/h) 0.02 0.02, 0.02 0.02 0.02, 0.02 0.02 0.02, 0.02 0.02 0.02, 0.03
CLu/F (L/h) 759.82 571.61, 948.03 892.82 704.75, 1080.89 987.83 743.83, 1231.83 1063.83 758.24, 1369.43
a 95 % PI refers to the 95 % confidence interval for the prediction value
AUC?, u, area under the plasma-concentration time curve from time zero to infinitypercent unbound, CLu/F oral clearance of unbound
fasiglifam, Cmax, u maximum observed unbound plasma concentration, CrCl creatinine clearance, PI prediction interval; prediction was made at
the central value of each impairment range, Tmax time to maximum plasma concentration, kz terminal elimination rate constant
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was not substantially different between subjects with nor-
mal renal function and those with renal impairment. In
addition, both mean Cmax,u and AUC?,u values for fasi-
glifam trended lower as renal function decreased from mild
to severe. Although regression analyses showed nonstatis-
tically significant linear relationships, as renal function
decreased from normal to severe, the predicted Cmax,u and
AUC?,u values decreased by as much as 21 % from those
observed in subjects with normal renal function. None-
theless, because the differences in mean Cmax,u and
AUC?,u values were relatively small between the renal
function groups, the changes in exposure to fasiglifam in
subjects with mild, moderate, or severe renal impairment
may not be considered clinically meaningful, but would
need to be confirmed after long-term clinical studies have
been conducted.
In contrast to the parent drug, mean plasma concentrations
of fasiglifam M-1 increased in subjects with mild, moderate,
and, most notably, severe renal impairment. Linear regres-
sion analyses showed a statistically significant linear trend
between M-1 Cmax and renal function, as measured by CLCR.
However, the observed increases in fasiglifam M-1 exposure
in subjects with renal impairment may be of little clinical
relevance, because in vitro studies have shown that fasigli-
fam M-1 does not bind to recombinant GPR40 (unpublished
data). Additional data are needed to further understand if
fasiglifam M-1 has any biological impact. The observed
levels of fasiglifam M-1 exposure in subjects with mild,
moderate, or severe renal impairment was lower than that
seen when doses of 400 or 800 mg fasiglifam were admin-
istered to healthy volunteers [19]. Renal clearance of fasi-
glifam and fasiglifam M-1 in subjects with normal renal
function or with mild, moderate, or severe renal impairment
varied from 0.001 to 0.002 L/h and 0.009 to 0.029 L/h,
respectively. Although renal impairment did not appear to
affect the CLR of fasiglifam, it had a more substantial effect
on the CLR of metabolite M-1. The decrease in CLR of M-1 is
likely responsible for the observed increase in M-1 exposure
with decreasing renal function.
The effect of renal insufficiency on CLR in individuals
with normal renal function or some degree of renal impair-
ment observed in this investigation is in line with a previous
study that showed that the CLR of fasiglifam and fasiglifam
M-1 in healthy subjects was negligible [19]. Taken together,
these results suggest that fasiglifam and fasiglifam M-1 are
primarily eliminated by nonrenal routes, including hepatic
metabolism. The minimal impact of renal insufficiency on
CLR may offer a therapeutic advantage to fasiglifam as this
suggests that it may be administered to patients with renal
impairment without further dose adjustments. Larger clinical
trials in patients with T2DM and renal impairment who are
receiving multiple doses of fasiglifam are needed to assess
the overall efficacy and safety in this patient population
before any clinical recommendations can be made.
Recent estimates suggest that diabetes is the leading
cause of kidney failure and accounted for 44 % of new
cases of ESRD in 2008 [22]. In this study, when subjects
with ESRD requiring dialysis were administered a single
50-mg oral dose of fasiglifam, arterial and venous plasma
concentrations of fasiglifam and its metabolite were nearly
equivalent during dialysis. These results suggest that only a
small fraction, if any, of fasiglifam or fasiglifam M-1 is lost
from the blood during dialysis.
A single dose of fasiglifam was well tolerated in this
study population of subjects with varying degrees of renal
function, and AEs varied from mild to moderate in inten-
sity. Previous studies have shown a low incidence of
hypoglycemia in T2DM patients who were administered
multiple doses of fasiglifam (6.25–400 mg) [15, 17]. This
Fig. 4 Scatter plots of fasiglifam a Cmax,u and b AUC?,u following
the administration of a single 50-mg dose of fasiglifam to subjects
with varying degrees of renal function. Horizontal bar represents the
mean. aESRD requiring dialysis. CLCR creatinine clearance. Normal
normal renal function, CLCR C90 mL/min; Mild mild renal impair-
ment, CLCR = 60 to \90 mL/min; Moderate moderate renal impair-
ment, CLCR = 30 to \60 mL/min; Severe severe renal impairment,
CLCR \30 mL/min; ESRD end-stage renal disease; AUC?,u area
under the plasma concentration-time curve from time 0 to infinity for
unbound drug; Cmax,u maximum observed plasma concentration for
unbound drug
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study adds to the increasing body of evidence suggesting a
low occurrence of hypoglycemia associated with fasigli-
fam, as no incident of hypoglycemia was observed after a
single dose of fasiglifam in any of the subjects with normal
renal function, renal impairment, or ESRD.
In conclusion, renal function status did not have a sig-
nificant impact on clearance of fasiglifam in this study,
suggesting that dose adjustments would not be required for
patients with renal impairment. Additionally, hemodialysis
had no effect on plasma exposure of fasiglifam or its
metabolite. Since the completion of this study, the fasi-
glifam clinical development program has been terminated
as a result of liver safety concerns. This study, however,
may provide useful data to aid in the development of other
similar antidiabetic compounds.
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